文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

无内脏利什曼病既往史的黑热病后皮肤利什曼病

Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.

作者信息

Hasnain Golam, Shomik Mohammad Sohel, Ghosh Prakash, Rashid Mamun Or, Hossain Shakhawat, Hamano Shinjiro, Mondal Dinesh

机构信息

Centre for Clinical Epidemiology and Biostatistics (CCEB), School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle (UoN), New South Wales, Australia.

Nutrition and Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

出版信息

Am J Trop Med Hyg. 2016 Dec 7;95(6):1383-1385. doi: 10.4269/ajtmh.16-0230. Epub 2016 Sep 26.

DOI:10.4269/ajtmh.16-0230
PMID:27672208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5154454/
Abstract

Post-kala-azar dermal leishmaniasis (PKDL) without previous visceral leishmaniasis (VL) is a rare dermatological manifestation of Leishmania infection. To date, most of the reported cases neither showed parasitological confirmation nor explained the outcome of treatment. Herein, we report three confirmed cases that were were successfully cured after miltefosine treatment.

摘要

无既往内脏利什曼病（VL）的黑热病后皮肤利什曼病（PKDL）是利什曼原虫感染罕见的皮肤表现。迄今为止，大多数报告病例既未显示寄生虫学确诊，也未说明治疗结果。在此，我们报告3例确诊病例，经米替福新治疗后成功治愈。

相似文献

[1]
Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.

Am J Trop Med Hyg. 2016-12-7

[2]
Advanced case of PKDL due to delayed treatment: A rare case report.

PLoS Negl Trop Dis. 2020-3-23

[3]
Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.

Am J Trop Med Hyg. 2009-3

[4]
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.

Trop Med Int Health. 2012-8-12

[5]
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.

J Infect Dis. 2020-2-3

[6]
Antimony susceptible : evidence from drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.

Microbiol Spectr. 2024-6-4

[7]
Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.

Acta Derm Venereol. 2014-3

[8]
Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.

J Vector Borne Dis. 2020

[9]
Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.

Ann Trop Med Parasitol. 2009-12

[10]
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.

PLoS Negl Trop Dis. 2012-5-22

引用本文的文献

[1]
Post kala-azar dermal leishmaniasis burden at the village level in selected high visceral leishmaniasis endemic upazilas in Bangladesh.

Int J Infect Dis. 2024-10

[2]
Post-Kala-Azar Dermal Leishmaniasis.

Am J Trop Med Hyg. 2024-7-23

[3]
Gauging the skin resident Leishmania parasites through a loop mediated isothermal amplification (LAMP) assay in post-kala-azar dermal leishmaniasis.

Sci Rep. 2022-10-27

[4]
Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment.

PLoS Negl Trop Dis. 2018-9-17

[5]
Case Report: Treatment of Widespread Nodular Post kala-Azar Dermal Leishmaniasis with Extended-Dose Liposomal Amphotericin B in Bangladesh: A Series of Four Cases.

Am J Trop Med Hyg. 2017-10

本文引用的文献

[1]
Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.

BMC Public Health. 2015-10-26

[2]
Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.

ScientificWorldJournal. 2015

[3]
How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data.

PLoS Negl Trop Dis. 2014-8-21

[4]
Biomarkers for intracellular pathogens: establishing tools as vaccine and therapeutic endpoints for visceral leishmaniasis.

Clin Microbiol Infect. 2014-6

[5]
A case of miltefosine responsive pleomorphic post kala-azar dermal leishmaniasis.

Braz J Infect Dis. 2013

[6]
Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.

Am J Trop Med Hyg. 2013-7-1

[7]
Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial.

Trop Med Int Health. 2012-11-8

[8]
Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.

Br J Dermatol. 2011-8

[9]
Enhanced case detection and improved diagnosis of PKDL in a Kala-azar-endemic area of Bangladesh.

PLoS Negl Trop Dis. 2010-10-5

[10]
Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh.

Clin Infect Dis. 2010-1-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索